Management of Venous Leg Ulcers

Publication Date: August 1, 2014
Last Updated: September 2, 2022

Diagnosis

Definition

We suggest use of a standard definition of venous ulcer as an open skin lesion of the leg or foot that occurs in an area affected by venous hypertension. (BP)
685

Treatment

Wound Care

Wound Cleansers

We suggest that venous leg ulcers be cleansed initially and at each dressing change with a neutral, nonirritating, nontoxic solution, performed with a minimum of chemical or mechanical trauma. (2-C)
685

Débridement

We recommend that venous leg ulcers receive thorough débridement at their initial evaluation to remove obvious necrotic tissue, excessive bacterial burden, and cellular burden of dead and senescent cells. (1-B)
685
We suggest that additional maintenance débridement be performed to maintain the appearance and readiness of the wound bed for healing. (2-B)
685
We suggest that the health care provider choose from a number of débridement methods, including sharp, enzymatic, mechanical, biologic, and autolytic. More than one débridement method may be appropriate. (2-B)
685

Anesthesia for Surgical Débridement

We recommend that local anesthesia (topical or local injection) be administered to minimize discomfort associated with surgical venous leg ulcer débridement. In selected cases, regional block or general anesthesia may be required. (1-B)
685

Surgical Débridement

We recommend that surgical débridement be performed for venous leg ulcers with slough, nonviable tissue, or eschar. Serial wound assessment is important in determining the need for repeated débridement. (1-B)
685

Hydrosurgical Débridement

We suggest hydrosurgical débridement as an alternative to standard surgical débridement of venous leg ulcers. (2-B)
685

Ultrasonic Débridement

We suggest against ultrasonic débridement over surgical débridement in the treatment of venous leg ulcers. (2-C)
685

Enzymatic Débridement

We suggest enzymatic débridement of venous leg ulcers when no clinician trained in surgical débridement is available to débride the wound. (2-C)
685
We do NOT suggest enzymatic débridement over surgical débridement. (2-C)
685

Biologic Débridement

We suggest that larval therapy for venous leg ulcers can be used as an alternative to surgical débridement. (2-B)
685

Management of Limb Cellulitis

We recommend that cellulitis (inflammation and infection of the skin and subcutaneous tissue) surrounding the venous leg ulcer be treated with systemic gram-positive antibiotics. (1-B)
685

Wound Colonization and Bacterial Biofilms

We suggest against systemic antimicrobial treatment of venous leg ulcer colonization or biofilm without clinical evidence of infection (2-C)
685

Treatment of Wound Infection

We suggest that venous leg ulcers with >106 colony-forming units per gram of tissue (CFU/g) and clinical evidence of infection be treated with antimicrobial therapy. (2-C)
685
We suggest antimicrobial therapy for virulent or difficult to eradicate bacteria (such as beta-hemolytic streptococci, pseudomonas, and resistant staphylococcal species) at lower levels of CFU/g. (2-C)
685
We suggest a combination of mechanical disruption and antibiotic therapy as most likely to be successful in eradicating venous leg ulcer infection. (2-C)
685

Systemic Antibiotics

We recommend that venous leg ulcers with clinical evidence of infection be treated with systemic antibiotics guided by sensitivities performed on wound culture. (1-C)
685
Oral antibiotics are preferred initially, and the duration of antibiotic therapy should be limited to 2 weeks unless persistent evidence of wound infection is present. (1-C)
685

Topical Antibiotics for Infected Wounds

We suggest against use of topical antimicrobial agents for the treatment of infected venous leg ulcers. (2-C)
685

Topical Dressing Selection

We suggest applying a topical dressing that will manage venous leg ulcer exudate and maintain a moist, warm wound bed. (2-C)
685
We suggest selection of a primary wound dressing that will absorb wound exudate produced by the ulcer (alginates, foams) and protect the periulcer skin. (2-B)
685

Topical Dressings Containing Antimicrobials

We recommend against the routine use of topical antimicrobial-containing dressings in the treatment of noninfected venous leg ulcers. (2-A)
685

Periulcer Skin Management

We suggest application of skin lubricants underneath compression to reduce dermatitis that commonly affects periulcer skin. (2-C)
685
In severe cases of dermatitis associated with venous leg ulcers, we suggest topical steroids to reduce the development of secondary ulcerations and to reduce the symptoms of dermatitis. (2-C)
685

Anti-inflammatory Therapies

We suggest against use of anti-inflammatory therapies for the treatment of venous leg ulcers. (2-C)
685

Indications for Adjuvant Therapies

We recommend adjuvant wound therapy options for venous leg ulcers that fail to demonstrate improvement after a minimum of 4–6 weeks of standard wound therapy. (1-B)
685

Split-thickness Skin Grafting

We suggest against split-thickness skin grafting as primary therapy in treatment of venous leg ulcers. (2-B)
685
We suggest split-thickness skin grafting with continued compression for selected large venous leg ulcers that have failed to show signs of healing with standard care for 4–6 weeks. (2-B)
685

Cellular Therapy

We suggest the use of cultured allogeneic bilayer skin replacements (with both epidermal and dermal layers) to increase the chances for healing in patients with difficult to heal venous leg ulcers in addition to compression therapy in patients who have failed to show signs of healing after standard therapy for 4–6 weeks. (2-A)
685

Preparation for Cellular Therapy

We suggest a therapeutic trial of appropriate compression and wound bed moisture control before application of cellular therapy. (2-C)
685
We recommend that adequate wound bed preparation, including complete removal of slough, debris, and any necrotic tissue, be completed before the application of a bilayered cellular graft. (1-C)
685
We recommend additional evaluation and management of increased bioburden levels before the application of cellular therapy. (1-C)
685

Frequency of Cellular Therapy Application

We suggest reapplication of cellular therapy as long as the venous leg ulcer continues to respond on the basis of wound documentation. (2-C)
685

Tissue Matrices, Human Tissues, or Other Skin Substitutes

We suggest the use of a porcine small intestinal submucosal tissue construct in addition to compression therapy for the treatment of venous leg ulcers that have failed to show signs of healing after standard therapy for 4–6 weeks. (2-B)
685

Negative Pressure Therapy

We suggest against routine primary use of negative pressure wound therapy for venous leg ulcers. (2-C)
685

Electrical Stimulation

We suggest against electrical stimulation therapy for venous leg ulcers. (2-C)
685

Ultrasound Therapy

We suggest against routine ultrasound therapy for venous leg ulcers. (2-B)
685

Overview

Title

Management of Venous Leg Ulcers

Authoring Organizations

American Venous Forum

Society for Vascular Surgery